Netherlands (Jurisdiction Profile)
Jurisdiction Identity
Cannabis Framework
| Dimension |
Status |
| Adult-use possession |
Tolerated under the Opium Act (adults 18+; up to 5 g tolerated in practice) |
| Adult-use cultivation |
Not legal (backdoor supply historically unregulated; experiment licenses growers) |
| Adult-use commercial supply |
Coffeeshops tolerated; Controlled Cannabis Supply Chain Experiment (April 7, 2025) tests licensed supply in participating municipalities |
| Medical access |
Office of Medicinal Cannabis (BMC) licenses medical cannabis producers; prescribed via pharmacies |
| Pharmaceutical cannabinoid access |
GMP-produced cannabis for medicinal purposes (BMC framework) |
| Home cultivation |
Prohibited |
| Import/export |
Regulated; BMC manages medical cannabis procurement (GMP) |
Regulatory Overview
The Netherlands operates a tolerance (“gedoog”) policy under the Opium Act: sale of up to 5 g in licensed coffeeshops is not prosecuted, while the supply side was historically unregulated (the “backdoor problem”). The Controlled Cannabis Supply Chain Experiment (wietexperiment) launched April 7, 2025: ten municipalities participate, and licensed growers legally supply participating coffeeshops. One-year results (April 2026) were reported as largely successful, with fines issued for non-compliance.
Regulatory History
- 1976: Opium Act reform establishes the tolerance policy.
- 2003: Office of Medicinal Cannabis (BMC) established for medical supply.
- 2020–2024: Experiment legislation and grower selection (10 growers).
- April 7, 2025: Experiment operational in participating municipalities.
- 2026: Experiment extended; results evaluated.
Licensing Structure
- Experiment growers: up to ten licensed growers supply participating coffeeshops (quality-controlled production).
- Medical producers: licensed under BMC/GMP for medicinal cannabis.
- Coffeeshops remain locally licensed under tolerance rules.
Laboratory / Quality Framework
- Experiment supply is quality-controlled (defined standards, laboratory analysis) — a move toward regulated quality for the non-medical chain.
- Medical cannabis is produced under GMP and tested per pharmaceutical standards.
- Public data: no public per-batch COA database located.
Data Surface
| Data surface |
Available? |
Official source |
Machine-readable? |
Notes |
| License registry |
partial |
Government experiment pages |
no |
Grower/participant lists published; no API |
| Testing-laboratory registry |
no public source located |
— |
— |
No distinct public list located |
| Laboratory testing rules |
yes |
Experiment regulations + Opium Act |
no |
Codified requirements |
| Contaminant/action limits |
yes |
Experiment standards |
no |
Set in standards |
| Recalls/advisories |
partial |
NVWA / government notices |
no |
Food-safety style notices; not cannabis-specific feed |
| Product/package identifiers |
no public source located |
— |
— |
Experiment products tracked internally |
| COAs/batch results |
no public source located |
— |
— |
Not public |
| Sales data |
partial |
Experiment evaluation reports |
no |
Aggregate evaluation data |
| Open-data downloads |
no public source located |
— |
— |
No cannabis open-data portal located |
Future Ingestion Opportunities
- Experiment evaluation reports (government.nl) — aggregate dataset records.
- BMC medical cannabis producer information — reference records.
- Track the experiment outcome: a national decision on regulated supply could follow evaluation.
Sources & Provenance
Graph Connections
No existing repository entities are linked to the Netherlands. The page is discoverable from the Jurisdictions index.